Summary：**Sakar Secures Landmark 40th Oncology Deal with Zydus for GCC Region***Introduction* Sakar Pharmac

**Sakar Secures Landmark 40th Oncology Deal with Zydus for GCC Region**

*Introduction*
Sakar Pharmaceuticals announced on Monday that it has finalized its 40th oncology licensing agreement, this time with Indian drugmaker Zydus Lifesciences. The partnership focuses on bringing Zydus’ portfolio of targeted cancer therapies to the Gulf Cooperation Council (GCC) market, a region where demand for advanced oncology treatments has risen sharply over the past five years. The deal marks a significant milestone for Sakar, underscoring its expanding role as a conduit for innovative medicines across the Middle East.

*Key Developments*
Under the terms of the agreement, Sakar will obtain exclusive rights to register, promote, and distribute three of Zydus’ flagship oncology products— a HER2‑inhibitor for breast cancer, a PARP inhibitor approved for ovarian carcinoma, and a next‑generation EGFR blocker for non‑small‑cell lung cancer. The arrangement includes technology transfer for local formulation, joint medical‑education initiatives, and a shared pharmacovigilance system to monitor safety outcomes in real time. Financial details were not disclosed, but industry sources estimate the upfront payment coupled with milestone‑based royalties could exceed $120 million over the contract’s five‑year term.

*Industry Analysis*
The GCC oncology market is projected to grow at a compound annual rate of 9.2 % through 2028, driven by increasing cancer incidence, government‑backed screening programs, and rising healthcare expenditure. Analysts note that multinational firms often struggle to navigate the heterogeneous regulatory landscapes of Saudi Arabia, the UAE, Qatar, and Oman. By partnering with a locally entrenched player like Sakar, Zydus gains faster market access while mitigating compliance risk. Conversely, Sakar strengthens its therapeutic pipeline, diversifying beyond its traditional focus on generics and biosimilars. The deal also reflects a broader trend of Indian pharmaceutical companies leveraging their cost‑effective R&D capabilities to supply high‑value specialty drugs to emerging markets.

*Future Outlook*
Both companies intend to launch the first product— the HER2‑inhibitor— in the UAE and Saudi Arabia by Q2 2026, followed by staggered rollouts across the remaining GCC states. Sakar